• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于绩效的耐多药结核病应对技术支持:来自绿灯委员会的经验教训。

Performance-based technical support for drug-resistant TB responses: lessons from the Green Light Committee.

机构信息

Global Fund to Fight AIDS, Tuberculosis and Malaria. Geneva.

World Health Organization. Geneva, Switzerland.

出版信息

Int J Tuberc Lung Dis. 2020 Jan 1;24(1):22-27. doi: 10.5588/ijtld.19.0376.

DOI:10.5588/ijtld.19.0376
PMID:32005303
Abstract

Drug-resistant tuberculosis (DR-TB) constitutes a global threat and a major contributor to deaths related to antimicrobial resistance. Despite progress in DR-TB detection and treatment over the last decade, huge gaps remain in treatment coverage, access to quality care and treatment outcome. Global Fund investments have been critical to scaling up the existing and new diagnostic tools, treatment coverage and people-centred service delivery. The United Nations General Assembly (UNGA) high-level meeting represents unprecedented opportunities to accelerate towards addressing DR-TB. Established in 2000 and funded by the Global Fund since 2009, the Green Light Committee (GLC) mechanism has evolved from project approval to providing demand-based technical assistance to countries to scale up response to DR-TB based on their need and priorities. Lessons learnt from the GLC mechanism over 10 years demonstrate that a result-based, systematic and accountable technical assistance model to support scale-up of DR-TB response is critically important. Meeting the UNGA declaration targets requires major scale-up of current efforts and new tools, and hence the need for predictable, consistent and sustained technical support to countries, including through the regional GLC mechanism. The application of the principles and processes of this model could be adapted and replicated to design a similar performance-based and quality-assured technical support mechanism.

摘要

耐多药结核病(DR-TB)构成了全球性威胁,也是导致与抗微生物药物耐药相关死亡的主要原因之一。尽管在过去十年中,DR-TB 的检测和治疗取得了进展,但在治疗覆盖面、获得优质护理和治疗结果方面仍存在巨大差距。全球基金的投资对于扩大现有和新的诊断工具、治疗覆盖面以及以患者为中心的服务提供至关重要。联合国大会(UNGA)高级别会议代表着加快解决耐多药结核病问题的前所未有的机会。绿色信号灯委员会(GLC)机制成立于 2000 年,自 2009 年以来一直由全球基金供资,该机制已经从项目审批演变为根据各国的需求和优先事项,为扩大耐多药结核病应对提供基于需求的技术援助。10 年来,从 GLC 机制中吸取的经验教训表明,基于成果、系统和问责的技术援助模式对于支持扩大耐多药结核病应对至关重要。要实现联合国大会宣言的目标,需要大幅扩大当前的努力和新工具,因此需要向各国提供可预测、持续和稳定的技术支持,包括通过区域 GLC 机制提供这种支持。该模式的原则和流程可以进行调整和复制,以设计类似的基于绩效和质量保证的技术支持机制。

相似文献

1
Performance-based technical support for drug-resistant TB responses: lessons from the Green Light Committee.基于绩效的耐多药结核病应对技术支持:来自绿灯委员会的经验教训。
Int J Tuberc Lung Dis. 2020 Jan 1;24(1):22-27. doi: 10.5588/ijtld.19.0376.
2
Tuberculosis结核病
3
Situational analysis of 10 countries with a high burden of drug-resistant tuberculosis 2 years post-UNHLM declaration: progress and setbacks in a changing landscape.10 个耐多药结核病高负担国家在联合国 HLCM 宣言发布 2 年后的形势分析:变化中的进展与挫折。
Int J Infect Dis. 2021 Jul;108:557-567. doi: 10.1016/j.ijid.2021.06.022. Epub 2021 Jun 15.
4
Drug resistant tuberculosis in Italy through a global health lens.从全球健康视角看意大利的耐药结核病。
New Microbiol. 2023 May;46(2):120-132.
5
[Development of antituberculous drugs: current status and future prospects].[抗结核药物的研发:现状与未来前景]
Kekkaku. 2006 Dec;81(12):753-74.
6
The Changing Paradigm of Drug-Resistant Tuberculosis Treatment: Successes, Pitfalls, and Future Perspectives.耐药结核病治疗范式的转变:成功、陷阱与未来展望。
Clin Microbiol Rev. 2022 Dec 21;35(4):e0018019. doi: 10.1128/cmr.00180-19. Epub 2022 Oct 6.
7
Development of a standardised multidrug-resistant/extensively drug-resistant tuberculosis assessment and monitoring tool.一种标准化耐多药/广泛耐药结核病评估与监测工具的开发。
Int J Tuberc Lung Dis. 2009 Oct;13(10):1305-8.
8
Strategies to Enhance Diagnostic Capabilities for the New Drug-Resistant Tuberculosis (DR-TB) Drugs.提高新型耐多药结核病(DR-TB)药物诊断能力的策略。
Pathogens. 2024 Nov 28;13(12):1045. doi: 10.3390/pathogens13121045.
9
Impact of multiple policy interventions on the screening and diagnosis of drug-resistant tuberculosis patients: a cascade analysis on six prefectures in China.多种政策干预对耐药结核病患者筛查和诊断的影响:中国六个地级市的级联分析。
Infect Dis Poverty. 2021 Jan 19;10(1):8. doi: 10.1186/s40249-021-00793-9.
10
The 2023 Latin America report of the Countdown on health and climate change: the imperative for health-centred climate-resilient development.《2023年健康与气候变化倒计时拉丁美洲报告:以健康为中心的气候适应型发展的必要性》
Lancet Reg Health Am. 2024 Apr 23;33:100746. doi: 10.1016/j.lana.2024.100746. eCollection 2024 May.

引用本文的文献

1
A survey of the effectiveness of centralized consilia in providing advice on drug-resistant TB.关于集中会诊在提供耐多药结核病治疗建议方面有效性的一项调查。
IJTLD Open. 2024 Jul 1;1(7):329-331. doi: 10.5588/ijtldopen.24.0228. eCollection 2024 Jul.
2
Progress on diagnosis and treatment of drug-resistant tuberculosis in line with World Health Organization recommendations in six priority countries in the Western Pacific Region.世界卫生组织西太平洋区域六个优先国家符合世卫组织建议的耐药结核病防治进展。
Western Pac Surveill Response J. 2022 Dec 19;13(4):1-12. doi: 10.5365/wpsar.2022.13.4.972. eCollection 2022 Oct-Dec.